#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pyoderma gangrenosum Autoimmune disorder Adenocarcinoma pancreas Acute lymphocytic leukaemia Acute graft versus host disease in intestine Cystic fibrosis respiratory infection suppression Malignant neoplasm of choroid Urethral valves T-cell lymphoma Oropharyngeal squamous cell carcinoma Hereditary hypophosphataemic rickets B precursor type acute leukaemia Systemic lupus erythematosus Depression Medulloblastoma recurrent More trials…

    Learn about Rare Diseases

    Alveolar rhabdomyosarcoma – Life with Disease Myxofibrosarcoma – Basic Information Hairy cell leukaemia – Basic Information Angiosarcoma – Diagnostics Antisynthetase syndrome – Life with Disease Atypical haemolytic uraemic syndrome – Trials in Disease Osteosarcoma – Basic Information Systemic mastocytosis Lennox-Gastaut syndrome – Diagnostics Toxic epidermal necrolysis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-ALANINE Defactinib ALG-000184 Pp1815 Icosapent Ethyl Lazertinib Falbikitug ATIRMOCICLIB Cladribine Autologous Pancreatic Islets Dl-Alpha-Tocopherol Edg-5506 Db-1303 Corifollitropin Alfa Levetiracetam Metamizole Sodium Monohydrate Epcoritamab Bicalutamide Azetukalner Mps-200 More therapies…

    Learn about Your Condition

    Basal cell naevus syndrome Diabetic nephropathy Oesophageal disorder Vaginal haemorrhage Pleural mesothelioma Osteogenesis imperfecta Myofascial pain syndrome Vulvovaginal candidiasis Endometrial cancer stage III Schizoaffective disorder Joint stabilisation Pain Cough Lichen sclerosus Venous thrombosis limb More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Anaplastic large cell lymphoma T- and null-cell types

  • Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    • T-cell lymphoma
    • Follicular lymphoma
    Investigated Drugs:
    • Placebo
    Denmark
  • Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Brigatinib
    Austria Belgium Czechia Denmark Finland France +7
  • Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    • Inflammatory myofibroblastic tumour
    • Rhabdomyosarcoma
    Investigated Drugs:
    • Temsirolimus
    • Crizotinib
    Denmark Finland France Germany Italy The Netherlands +3
  • Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    Investigated Drugs:
    • Vinblastine Sulfate
    Austria Belgium Denmark Finland France Germany +2
  • Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    Investigated Drugs:
    • Lorlatinib
    Italy
  • Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    Investigated Drugs:
    • Nivolumab
    Denmark France
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!